Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Exp Clin Endocrinol Diabetes ; 119(8): 497-501, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21915844

ABSTRACT

Statins have marked beneficial effects on lipid profile, but also have pleiotropic actions. A previous study in an iodine-deficient area suggested that statin use is associated with reduced thyroid volume and nodularity. We performed this study to investigate how long-term statin use in type 2 diabetic patients affects thyroid nodularity in iodine-sufficient area.We recruited euthyroid type 2 diabetic patients, receiving statin therapy continuously for at least 5 years (statin group) and, age and sex matched statin-naive type 2 diabetic patients (control group). Subjects with past history of cancer, thyroid disease or treatment with lithium or amiodarone; family history of thyroid cancer; palpable goiter or thyroid nodule, and/or positive thyroperoxidase antibody were excluded. The prevalence, number, and volume of thyroid nodules, size of thyroid were evaluated in all subjects by high resolution ultrasound.Prevalence of non-palpable thyroid nodules of statin group (n=70) and control group (n=98) were 51 and 53%, respectively. There was no difference of prevalence, number, and volume of non-palpable thyroid nodules and size of thyroid between statin and control group. But, the patients aged between 60 and 65 years from statin group showed lower prevalence of non-palpable thyroid nodules than the patients with same age interval from control group (4 out of 12 patients, 33%, statin group; 19 out of 27 patients, 70%, control group; P=0.04).Long-term statin use in elderly type 2 diabetic patients was associated with lesser prevalence of thyroid nodules in an iodine-sufficient area. Our data might support a possible antiproliferative effect of statins on thyroid in old type 2 diabetic patients. But, the effect was not as strong as that in an iodine-deficient area and further studies with enough numbers of subjects and revised design will be needed.


Subject(s)
Diabetes Mellitus, Type 2/complications , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hyperlipidemias/drug therapy , Hypolipidemic Agents/therapeutic use , Thyroid Nodule/prevention & control , Age Factors , Aged , Cell Proliferation/drug effects , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Hyperlipidemias/complications , Hypolipidemic Agents/administration & dosage , Hypolipidemic Agents/adverse effects , Iodine/administration & dosage , Male , Middle Aged , Organ Size/drug effects , Prevalence , Reproducibility of Results , Republic of Korea/epidemiology , Thyroid Gland/diagnostic imaging , Thyroid Gland/drug effects , Thyroid Gland/pathology , Thyroid Nodule/diagnostic imaging , Thyroid Nodule/epidemiology , Thyroid Nodule/pathology , Time Factors , Tumor Burden/drug effects , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL